BPC- 157 Acetate - 6MG

BPC-157 Regenerative Profile

BPC-157 is a stable gastric pentadecapeptide with broad regenerative properties, demonstrated to accelerate healing in muscle, tendon, ligament, and gastrointestinal tissues. Preclinical studies consistently show that BPC-157 enhances wound healing by promoting angiogenesis, modulating growth factor pathways, and supporting rapid resolution of vessel constriction and clot formation, which are critical for tissue repair.^[1][2] Its efficacy extends to the healing of complex wounds, including skin, colocutaneous, gastrocutaneous, and other fistulas, as well as deep burns and diabetic ulcers.^[1][3]

In musculoskeletal models, BPC-157 has been shown to improve healing of tendon, ligament, and muscle injuries, with effects comparable to or exceeding those of standard angiogenic growth factors such as EGF, FGF, and VEGF, but with a broader spectrum of action and consistent efficacy across different tissue types.^[2] The peptide’s angiogenic and cytoprotective effects are central to its ability to restore tissue integrity and function following injury.^[2][4]

Within the gastrointestinal tract, BPC-157 demonstrates potent anti-ulcer and mucosal protective effects, facilitating healing of both upper and lower GI lesions, including those induced by NSAIDs, alcohol, or surgical injury.^[5][6][7] It has also been shown to promote closure of gastrointestinal fistulas and improve outcomes in models of short bowel syndrome and failed anastomosis.^[3][8][6][9] BPC-157’s mechanism involves modulation of the nitric oxide (NO) system, protection of endothelium, and upregulation of genes involved in extracellular matrix formation and tissue remodeling.^[5][9]

Neuroprotective and organoprotective effects have also been described, with evidence of benefit in models of nerve injury, traumatic brain injury, and ischemia-reperfusion syndromes.^[10][11] BPC-157 is native to and stable in human gastric juice, and has demonstrated a favorable safety profile in early clinical trials, with no reported toxicity or significant adverse effects.^[1][12][9]

While BPC-157 is not currently approved by the FDA or other major regulatory agencies for standard medical use, and robust human clinical data remain limited, its regenerative and cytoprotective properties are well-supported in the preclinical literature.^[12] The typical experimental dosing in animal studies ranges from 10 ng/kg to 10 μg/kg, with 10 mg being a commonly referenced research dose, though optimal human dosing has not been established.^[8][6]

In summary, BPC-157 is a multifunctional peptide with demonstrated efficacy in accelerating healing of muscles, tendons, ligaments, and the gastrointestinal tract, acting through angiogenic, cytoprotective, and anti-inflammatory mechanisms.^{[1][2][3][5][4][6][9][7]}

References

1. Seiwerth S, Milavic M, Vukojevic J, et al. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533.
2. Seiwerth S, Rucman R, Turkovic B, et al. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447.
3. Sikiric P, Drmic D, Sever M, et al. Curr Pharm Des. 2020;26(25):2991-3000. doi:10.2174/1381612826666200424180139.
4. Sikiric P, Rucman R, Turkovic B, et al. Curr Pharm Des. 2018;24(18):1990-2001. doi:10.2174/1381612824666180608101119.
5. Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2017;23(27):4012-4028. doi:10.2174/1381612823666170220163219.
6. Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2011;17(16):1612-32. doi:10.2174/138161211796196954.
7. Park JM, Lee HJ, Sikiric P, Hahm KB. Curr Pharm Des. 2020;26(25):2971-2981. doi:10.2174/1381612826666200523180301.
8. Lojo N, Rasic Z, Zenko Sever A, et al. PLOS One. 2016;11(9):e0162590. doi:10.1371/journal.pone.0162590.
9. Sikiric P, Seiwerth S, Rucman R, et al. Curr Med Chem. 2012;19(1):126-32. doi:10.2174/092986712803414015.
10. Sikiric P, Seiwerth S, Rucman R, et al. Curr Neuropharmacol. 2016;14(8):857-865. doi:10.2174/1570159x13666160502153022.
11. Sikiric P, Skrtic A, Gojkovic S, et al. World J Gastroenterol. 2022;28(1):23-46. doi:10.3748/wjg.v28.i1.23.
12. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185.

All COA’s avail upon request by email info@truformlabs.com.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C (long-term). Short-term storage up to 2–3 weeks at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot into sterile vials and freeze at −20 °C for up to 3 months.
• Light & moisture: Protect from light; keep container tightly closed to avoid moisture uptake.
• Freeze–thaw: Avoid repeated freeze–thaw cycles (use aliquots).
• Solvent compatibility: Choose sterile solvent compatible with your protocol; filter-sterilize if required by your procedures.
• Labeling: Clearly label aliquots with concentration, solvent, and date of preparation.

Storage guidance is general for research peptides and may be adjusted per your lab SOP.